While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
The Tufts Center for the Study of Drug Development is out with a new study claiming that the average cost of bringing a new drug to market is around $2.6bn, though some are saying that number seems inflated.
The genomics industry is already separating into two tiers; the
winners are those focused on targets and drug development and which
have products in or near the clinic, as well as strong
partnerships, says analyst